CClinicalTrials.gg
Status unknownNCT04062747Updated Aug 20, 2019

The Effect Of I-Gel And Ambu Aura-I Use On Laryngofaryngeal Mucosa

An interventional study of I-gel and Ambu aura i in Mucosal Damage, sponsored by Bezmialem Vakif University. Status unknown at 1 site in Turkey. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Bezmialem Vakif University · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
Up to 2 Years
Sex
All
01

Study summary

Supraglottic airway devices (SGADs) are frequently preferred in surgical surgery for pediatric patients. i-gel LMA (laryngeal mask airway) and Ambu Aura-i LMA are the new generation supraglottic airway devices. The aim of this study was to compare airway trauma and postoperative complications due to i-gel and Ambu Aura in infants. In the study patients were divided into two groups performed on minor surgery ASA I (American Society of Anesthesiologists score) and 40 infants. After standard anesthesia i-Gel was placed into a group and Ambu Aura-i was placed to the other. Flexible bronchoscopy was performed at the end of surgery. Mucosal damage and postoperative complications in laryngopharyngeal structures were compared.

Read the detailed description

This study was conducted as prospective, randomized and double-blind study. After confirmation the approval from the Interventional Ethics Committee of the Bezmialem Vakif University, dated.... Number...., the study was started. Forty ASA I patients under the age of 1, with a body weight of more than 10 kg, without anatomical pathology in the upper airway with no general anesthesia within the last 2 weeks who underwent minor surgery (circumcision, inguinal hernia, undescended testis, hypospadias, etc.) by the Pediatric Surgery Clinic at Bezmialem Vakif University Medical School Hospital were included in the study. Patients who are older than 1 year of age and have a body weight of more than 10 kg, who have symptoms of upper or lower respiratory tract infection, who have more than one trial performed during the SADs placement, who are known and expected to be difficult airway, who has undergone surgery for more than 2 hours and patients who underwent emergency surgery were not included in the study.

02

Conditions studied

  • Mucosal Damage

Keywords

  • Laryngeal Mask
  • I-gel
  • Ambu Aura i
  • Flexible bronchoscopy
  • Laryngopharyngeal damage
  • Infant
03

In context

Lead sponsor

Bezmialem Vakif University is the lead sponsor of 345 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ASA I
  2. patients under the age of 1,
  3. body weight of less than 10 kg
  4. without anatomical pathology in the upper airway
  5. no general anesthesia within the last 2 weeks who underwent minor surgery

Exclusion criteria

Exclusion Criteria:

  1. older than 1 year of age
  2. body weight of more than 10 kg
  3. symptoms of upper or lower respiratory tract infection
  4. more than one trial performed during the SADs placement
  5. known and expected to be difficult airway
  6. undergone surgery for more than 2 hours and patients
  7. underwent emergency surgery
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    I-gel LMA

    After standard anesthesia i-Gel was placed into the patient.

    Device: I-gel

  • Active comparator
    Ambu Aura-i

    After standard anesthesia Ambu Aura-i was placed into the patient.

    Device: Ambu aura i

Interventions

  • DeviceI-gel

    After standard anesthesia i-Gel was placed into the patient

    Also known as: I-gel laryngeal mask airway

  • DeviceAmbu aura i

    After standard anesthesia ambu aura was placed into the patient

    Also known as: Ambu aura i laryngeal mask airway

06

What researchers measure

Primary outcomes

  1. airway trauma

    4 point scoring system 1- no hyperemia 2- mild hyperemia 3- severe hyperemia 4-mucosal damage and bleeding

    Time frame: up to 1 minute after extubation

07

Study locations

1 of 1 sites recruiting
  • Bezmialem Vakıf University
    Istanbul, Fatih 34093, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04062747
Lead sponsor
Bezmialem Vakif University
Responsible party
Sponsor
First posted
Aug 20, 2019
Start date
May 18, 2019
Primary completion
Sep 15, 2019 (estimated)
Completion
Sep 20, 2019 (estimated)
Last update
Aug 20, 2019

Study contacts

Sinan Yılmaz, Instructor
Contact
siyilmaz@bezmialem.edu.tr
+905324563023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion